Dyne Therapeutics, Inc. Common Stock DYN

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

• GlobeNewswire Inc. 21 jul

  Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock

  Dyne Therapeutics priced an upsized underwritten public offering of 18.3 million shares at $20.50 per share, generating gross proceeds of approximately $375.2 million. The offering is expected to close on July 23, 2026, with underwriters granted a 30-day option to purchase an additional 2.745 million shares. Morgan Stanley, Jefferies, and Evercore ISI are serving as joint book-running managers.

  

• GlobeNewswire Inc. 21 jul

  Dyne Therapeutics Announces Proposed Public Offering of Common Stock

  Dyne Therapeutics, a clinical-stage neuromuscular disease company, announced a $300 million underwritten public offering of common stock with a 30-day option for underwriters to purchase an additional $45 million. Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, and Raymond James are serving as joint book-running managers. The offering is subject to market conditions and SEC approval.

  

• The Motley Fool 26 jun

  Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

  The article compares two clinical-stage biotech companies: Dyne Therapeutics, which targets rare neuromuscular diseases using its FORCE platform, and Viking Therapeutics, which focuses on the larger weight-loss and metabolic disorder market with its VK2735 candidate. Both companies are unprofitable with significant cash burn, but the author recommends Viking due to the substantially larger market opportunity in obesity treatment, despite competitive pressures from industry giants like Eli Lilly and Novo Nordisk.